TCBP News & Events

CytoMed Therapeutics (GDTC) announced that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology of TC BioPharm, a subsidiary of TC BioPharm (TCBP). This follows CytoMed's announcement on October 14, 2025 regarding its proposed acquisition of potentially synergistic assets from TCBL.

TC BioPharm announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease, or MRD, is now in complete molecular remission following treatment with the lead drug candidate TCB008. The response was achieved after the patient's second dose of 250,000,000 gamma delta t-cells, two weeks after treatment began, in total the patient received approximately 500,000,000 gamma delta t-cells over two weeks. The patient received 2 of a possible 4 infusions of TCB008 and continues to be monitored under the care of Dr. Hugues de Lavallade at Guy's and St. Thomas' NHS Foundation Trust and remains in remission state two months after treatment. This data readout represents a major milestone in TC BioPharm's mission to develop innovative cell therapies that target and eradicate malignant cells with precision and durability. Over 1 million patients are diagnosed with blood cancers globally each year. Patients who initially achieve remission can retain a molecular burden of disease that results in relapse. Multiple factors, including previous treatments, limit treatment options for relapsed patients.

TC BioPharm announced that on March 20, 2025, it received notice that the Nasdaq Hearings Panel had determined to delist the company's securities from The Nasdaq Stock Market LLC due to the company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. Management is currently working on an appeal with Nasdaq. The company's securities will be suspended for trading on Nasdaq effective at the opening of trading on Monday, March 24, 2025. The company expects its American Depositary Shares to be eligible to trade on the OTC Markets effective with the opening of trading on Monday, March 24, 2025.

TC BioPharm announced initiatives to outsource several functions, moving to a more decentralized model, resulting in reduction in its workforce. The initiatives focus on moving to a CDMO model for production to accommodate larger production demand for future clinical trials, allowing TCB to review alternatives for new manufacturing facilities incorporating newly developed automated and other cell therapy production technologies. Additionally, the company is reviewing alternative approaches for testing and clinical needs, which align with a decentralized drug development model. This approach is expected to result in a workforce reduction of approximately 20 employees, focused largely within the company's production and quality divisions and represents approximately half of the company's total headcount. Separations will be substantially complete by the end of Q2 and are expected to reduce the core operational burn rate by approximately 55% compared to 2024. As a result of these steps, when compared to 2024, the company estimates partial year 2025 savings to be approximately $2.1M and annualized savings to be roughly $4.2M.